

<b>General information about company</b>	
Scrip code	524372
NSE Symbol	ORCHPHARMA
MSEI Symbol	NOTLISTED
ISIN	INE191A01027
Name of the entity	Orchid Pharma Limited
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Reporting Quarter Type	Yearly
Date of Quarter Ending	31-03-2025
Type of company	Equity
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No The company has not acquired any shares or voting rights in any unlisted company or no subsequent change has occurred during the Quarter ended on March 31, 2025. Therefore, Annexure 1 (Part c) of SEBI Circular dated December 31, 2024 is not applicable to the Company.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	Yes
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	Yes
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No In accordance to SEBI Circular dated December 31, 2024, the Disclosure is not applicable reason being the Company falls under the exemption category mentioned at Note. 1(b) of Annexure 1 (Part F) of above Circular.
Risk management committee	Applicable
Market Capitalisation as per immediate previous Financial Year	Top 1000 listed entities
Is SCORE ID Available ?	Yes
SCORE Registration ID	O00042
Reason For No SCORE ID	
Type of Submission	Original
Remarks (website dissemination)	
Remarks for Exchange (not for Website Dissemination)	

Annexure I								
Annexure I to be submitted by listed entity on quarterly basis								
I. Composition of Board of Directors								
Disclosure of notes on composition of board of directors explanatory								
Whether the listed entity has a Regular Chairperson							Yes	
Whether Chairperson is related to MD or CEO							No	
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Mr	Ram Gopal Agarwal		00627386	Non-Executive - Non Independent Director	Chairperson		30-07-1949
2	Mr	Manish Dhanuka		00238798	Executive Director	Not Applicable	MD	28-09-1967
3	Mr	Mridul Dhanuka		00199441	Executive Director	Not Applicable		20-10-1980
4	Mr	Arjun Dhanuka		00454689	Non-Executive - Non Independent Director	Not Applicable		10-03-1988
5	Mr	Dharam Vir		08771224	Non-Executive - Independent Director	Not Applicable		15-03-1961
6	Mr	Manoj Kumar Goyal		06361663	Non-Executive - Independent Director	Not Applicable		26-05-1976
7	Ms	Shubha Singh		06926872	Non-Executive - Independent Director	Not Applicable		26-01-1976
8	Ms	Tanu Singla		08774132	Non-Executive - Independent Director	Not Applicable		20-11-1985

<b>I. Composition of Board of Directors</b>					
<b>Disqualification of Directors under section 164 of the Companies Act, 2013</b>					
Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active
7	No				Active
8	No				Active

I. Composition of Board of Directors													
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	Yes	21-08-2024	31-03-2020				1	0	0	0			
2	NA		31-03-2020	28-02-2025			2	0	0	0			
3	NA		31-03-2020	28-02-2025			1	0	2	0			
4	NA		20-10-2023				1	0	0	0			
5	NA		29-06-2020	29-06-2020		57.02	1	1	1	1			
6	NA		29-06-2020	29-06-2020		57.02	1	1	2	1			
7	NA		23-05-2024	23-05-2024		10.09	3	2	3	2			
8	NA		29-06-2020	29-06-2020		57.02	1	1	2	0			

<b>Audit Committee Details</b>							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	06361663	Manoj Kumar Goyal	Non-Executive - Independent Director	Chairperson	29-06-2020		
2	08774132	Tanu Singla	Non-Executive - Independent Director	Member	29-06-2020		
3	00199441	Mridul Dhanuka	Executive Director	Member	31-03-2020		

<b>Nomination and remuneration committee</b>							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	08771224	Dharam Vir	Non-Executive - Independent Director	Chairperson	09-02-2023		
2	00454689	Arjun Dhanuka	Non-Executive - Non Independent Director	Member	21-05-2024		
3	06361663	Manoj Kumar Goyal	Non-Executive - Independent Director	Member	07-09-2020		
4	06926872	Shubha Singh	Non-Executive - Independent Director	Member	17-07-2024		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	08771224	Dharam Vir	Non-Executive - Independent Director	Chairperson	29-06-2020		
2	06361663	Manoj Kumar Goyal	Non-Executive - Independent Director	Member	07-09-2020		
3	08774132	Tanu Singla	Non-Executive - Independent Director	Member	29-06-2020		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	08771224	Dharam Vir	Non-Executive - Independent Director	Chairperson	22-05-2021		
2	00238798	Manish Dhanuka	Executive Director	Member	22-05-2021		
3	00199441	Mridul Dhanuka	Executive Director	Member	22-05-2021		
4	99999999	Sunil Kumar Gupta	Chief Financial Officer	Member	22-05-2021		Textual Information(1)
5	99999999	A Chandrasekar	Vice President-Operations	Member	11-11-2024		Textual Information(2)

<b>Sr Text Block</b>	
Textual Information(1)	Mr. Sunil Kumar Gupta is not a member of the Board of Directors of the Compoany. However, he is a member of Risk Management Committee, therefore dummy DIN has been filled.
Textual Information(2)	Mr. A Chandrasekar is not a member of the Board of Directors of the Compoany. However, he is a member of Risk Management Committee, therefore dummy DIN has been filled.

<b>Corporate Social Responsibility Committee</b>							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	08771224	Dharam Vir	Non-Executive - Independent Director	Chairperson	19-06-2023		
2	00238798	Manish Dhanuka	Executive Director	Member	19-06-2023		
3	00199441	Mridul Dhanuka	Executive Director	Member	19-06-2023		

<b>Other Committee</b>						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks
1	00238798	Manish Dhanuka	Banking, Finance and Operations Committee	Executive Director	Chairperson	
2	00199441	Mridul Dhanuka	Banking, Finance and Operations Committee	Executive Director	Member	

Annexure 1								
Annexure 1								
III. Meeting of Board of Directors								
Disclosure of notes on meeting of board of directors explanatory								
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	11-11-2024				Yes	8	8	4
2		12-02-2025	92		Yes	8	7	4

Annexure 1										
IV. Meeting of Committees										
Disclosure of notes on meeting of committees explanatory							Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/ No)				
1	Audit Committee	11-11-2024				Yes	3	3	2	0
2	Audit Committee	12-02-2025	92			Yes	3	3	2	0
3	Risk Management Committee	07-02-2025				Yes	3	2	1	2
4	Corporate Social Responsibility Committee	07-02-2025				Yes	3	2	1	0
5	Stakeholders Relationship Committee	11-11-2024				Yes	3	3	3	0

<b>Annexure 1</b>		
<b>V. Affirmations</b>		
Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

<b>Annexure 1</b>		
Sr	Subject	Compliance status
1	Name of signatory	Kapil Dayya
2	Designation	Company Secretary and Compliance Officer

<b>Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)</b>				
<b>I. Disclosure on website in terms of LODR Regulation</b>				
<b>Sr</b>				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
As per regulation 46(2) of the LODR:				
1.1	Details of business	Yes		<a href="https://www.orchidpharma.com/">https://www.orchidpharma.com/</a>
1.2	Memorandum of Association and Articles of Association	Yes		<a href="https://www.orchidpharma.com/downloads/Orchid%20MOA&amp;%20AOA.pdf">https://www.orchidpharma.com/downloads/Orchid%20MOA&amp;%20AOA.pdf</a>
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		<a href="https://www.orchidpharma.com/abt_management.html">https://www.orchidpharma.com/abt_management.html</a>
2	Terms and conditions of appointment of independent directors	Yes		<a href="https://www.orchidpharma.com/invr_corporategovernance.html">https://www.orchidpharma.com/invr_corporategovernance.html</a>
3	Composition of various committees of board of directors	Yes		<a href="https://www.orchidpharma.com/invr_comm_comp.html">https://www.orchidpharma.com/invr_comm_comp.html</a>
4	Code of conduct of board of directors and senior management personnel	Yes		<a href="https://www.orchidpharma.com/invr_corporategovernance.html">https://www.orchidpharma.com/invr_corporategovernance.html</a>
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		<a href="https://www.orchidpharma.com/downloads/Policy%20on%20%20Whistle%20Blower.pdf">https://www.orchidpharma.com/downloads/Policy%20on%20%20Whistle%20Blower.pdf</a>
6	Criteria of making payments to non-executive directors	Yes		<a href="https://www.orchidpharma.com/downloads/Criteria%20of%20making%20payment%20to%20Non-Executive%20Directors.pdf">https://www.orchidpharma.com/downloads/Criteria%20of%20making%20payment%20to%20Non-Executive%20Directors.pdf</a>
7	Policy on dealing with related party transactions	Yes		<a href="https://www.orchidpharma.com/downloads/Policy%20on%20RPT%20and%20Material%20RPT.pdf">https://www.orchidpharma.com/downloads/Policy%20on%20RPT%20and%20Material%20RPT.pdf</a>
8	Policy for determining 'material' subsidiaries	Yes		<a href="https://www.orchidpharma.com/downloads/Policy%20for%20Material%20Subsidiaries_v-2.0.pdf">https://www.orchidpharma.com/downloads/Policy%20for%20Material%20Subsidiaries_v-2.0.pdf</a>
9	Details of familiarization programmes imparted to independent directors	Yes		<a href="https://www.orchidpharma.com/invr_downloads.html">https://www.orchidpharma.com/invr_downloads.html</a>
10	Email address for grievance redressal and other relevant details	Yes		<a href="https://www.orchidpharma.com/invr_investor.html">https://www.orchidpharma.com/invr_investor.html</a>
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		<a href="https://www.orchidpharma.com/invr_con_authoff.html">https://www.orchidpharma.com/invr_con_authoff.html</a>
12	Financial results	Yes		<a href="https://www.orchidpharma.com/invr_financial.html">https://www.orchidpharma.com/invr_financial.html</a>
13	Shareholding pattern	Yes		<a href="https://www.orchidpharma.com/invr_shareholding.html">https://www.orchidpharma.com/invr_shareholding.html</a>
14	Details of agreements entered into with the media companies and/or their associates	NA		

<b>Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)</b>			
<b>I. Disclosure on website in terms of LODR Regulation</b>			
<b>Sr</b>			
	As per regulation 46(2) of the LODR:		
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes	<a href="https://www.orchidpharma.com/invr_conferencecalls.html">https://www.orchidpharma.com/invr_conferencecalls.html</a>
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	Yes	<a href="https://www.orchidpharma.com/invr_conferencecalls.html">https://www.orchidpharma.com/invr_conferencecalls.html</a>
16	New name and the old name of the listed entity	NA	
17	Advertisements as per regulation 47 (1)	Yes	<a href="https://www.orchidpharma.com/invr_intimation.html">https://www.orchidpharma.com/invr_intimation.html</a>
18	Credit rating or revision in credit rating obtained	Yes	<a href="https://www.orchidpharma.com/Invr_creditrating.html">https://www.orchidpharma.com/Invr_creditrating.html</a>
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes	<a href="https://www.orchidpharma.com/invr_downloads.html">https://www.orchidpharma.com/invr_downloads.html</a>
20	Secretarial Compliance Report	Yes	<a href="https://www.orchidpharma.com/invr_corporategovernance.html">https://www.orchidpharma.com/invr_corporategovernance.html</a>
21	Materiality Policy as per Regulation 30 (4)	Yes	<a href="https://www.orchidpharma.com/downloads/Policy%20on%20Materiality%20of%20events%20or%20Information.pdf">https://www.orchidpharma.com/downloads/Policy%20on%20Materiality%20of%20events%20or%20Information.pdf</a>
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes	<a href="https://www.orchidpharma.com/invr_con_authoff.html">https://www.orchidpharma.com/invr_con_authoff.html</a>
23	Disclosures under regulation 30(8)	Yes	<a href="https://www.orchidpharma.com/invr_intimation.html">https://www.orchidpharma.com/invr_intimation.html</a>
24	Statements of deviation(s) or variations(s) as specified in regulation 32	Yes	<a href="https://www.orchidpharma.com/invr_intimation.html">https://www.orchidpharma.com/invr_intimation.html</a>
25	Dividend Distribution policy as per Regulation 43A(1)	Yes	<a href="https://www.orchidpharma.com/invr_corporategovernance.html">https://www.orchidpharma.com/invr_corporategovernance.html</a>
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes	<a href="https://www.orchidpharma.com/invr_corporategovernance.html">https://www.orchidpharma.com/invr_corporategovernance.html</a>
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA	
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes	-
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes	-

<b>Annexure II</b>				
<b>II. Annual Affirmations</b>				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	No	All regulations were duly complied except that under Regulation 17(1A) Special Resolution for continuation of Directorship of Mr. Ram Gopal Agarwal, Non-Executive Director of the Company was passed 22 days after he attained the age of 75 Years. However, the said Resolution stated about the continuity of office from the day he attained 75 years of age.
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

<b>Annexure II</b>				
<b>II. Annual Affirmations</b>				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

<b>Annexure II</b>				
<b>II. Annual Affirmations</b>				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

<b>Annexure II</b>				
<b>II. Annual Affirmations</b>				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

<b>Annexure II</b>				
<b>II. Annual Affirmations</b>				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
	Any other information to be provided - Add Notes			

<b>Annexure II</b>		
1	Name of signatory	Kapil Dayya
2	Designation	Company Secretary and Compliance Officer

<b>Annexure II</b>		
<b>III. Affirmations</b>		
<b>Sr</b>	<b>Particulars</b>	<b>Compliance status (Yes/No/NA)</b>
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	Textual Information(1)

<b>Text Block</b>	
Textual Information(1)	The Company does not have any material subsidiary however the Compliances w.r.t the Subsidiary under Regulation 26 of Listing Regulations had been duly complied with.

<b>Annexure II</b>		
1	Name of signatory	Kapil Dayya
2	Designation	Company Secretary and Compliance Officer

<b>Details of Cyber security incidence</b>		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		No
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

<b>Signatory Details</b>	
Name of signatory	Kapil Dayya
Designation of person	Company Secretary and Compliance Officer
Place	Gurugram
Date	29-04-2025

<b>Investor Grievance Details</b>	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	2
No. of investor complaints disposed off during the Quarter	2
No. of investor complaints those remaining unresolved at the end of the Quarter	0

<b>Disclosure of Imposition of Fine or Penalty The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:</b>					
Any Other Information for Disclosure of Imposition of Fine or Penalty					
Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
1	BSE Limited	Imposition of fine amounting to Rs.44,000	17-03-2025	Non Compliance with the requirements of Regulation 17(1A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to appointment or continuation of Non-executive director who has attained the age of seventy-five years	No Impact as the Fine had been paid
2	National Stock Exchange of India Limited	Imposition of fine amounting to Rs.44,000	17-03-2025	Non Compliance with the requirements of Regulation 17(1A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to appointment or continuation of Non-executive director who has attained the age of seventy-five years	No Impact as the Fine had been paid

<b>Disclosure of Updates to Ongoing Tax Litigations or Disputes The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:</b>				
Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes				
Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
1	ASSISTANT COMMISSIONER VALLUVARKOTTAM ASSESSMENT CIRCLE	25-03-2024	the Company had filed an appeal before the GST Appeals Chennai-1	Hearing date is yet to be assigned
2	ASSISTANT COMMISSIONER VALLUVARKOTTAM CENTRAL-III CHENNAI CENTRAL	15-07-2024	the Company would appeal to the appropriate appellate authority/tribunal	Hearing date is yet to be assigned
3	ASSISTANT COMMISSIONER VALLUVARKOTTAM CENTRAL-III CHENNAI CENTRAL	26-09-2024	the Company would appeal to the appropriate appellate authority/tribunal	Hearing date is yet to be assigned

